Insight

Oct 10, 2024, 13:19

Myeloma Paper of the Day, October 10th, suggested by Robert Orlowski

Robert Orlowski shared about the Myeloma Paper of the Day. Read about the article on X below:

“Myeloma Paper of the Day: Study of Waldenström macroglobulinemia patients in China finds 87.8% MYD88 mutation rate, 30.9% CXCR4 mutation rate, and these mutations emerged as independent adverse prognostic factors in the BTKi treatment group.”

Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia

Authors: Yuting Yan, Ying Yu, Wenjie Xiong, Jun Wang, Yao Yao, Yujiao Jia, Yanshan Huang, Yuxi Li, Tingyu Wang, Rui Lv, Hao Sun, Haoxu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Zhen Yu, Dehui Zou, Mu Hao, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Shuhua Yi.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.